mohd izzuan TG Therapeutics is up ~17% Monday after issuing 2025 revenue guidance above consensus
Earnings Call Insights: TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Management View CEO Michael Weiss highlighted
*Other Operating Data Consensus Source: Bloomberg
TG Therapeutics press release (NASDAQ:TGTX): Q4 GAAP EPS of $0.15 beats by $0.06. Revenue of
TG Therapeutics (NASDAQ:TGTX) is scheduled to announce Q4 earnings results on Monday, March 3rd, before
Joao Serafim Citing preliminary financials, TG Therapeutics (NASDAQ:TGTX) announced Tuesday that the U.S. net sales
Summary: TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales
Summary: TG Therapeutics’ Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and
TG Therapeutics (NASDAQ:TGTX) has signed a multi-year manufacturing supply agreement with FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY)
TG Therapeutics press release (NASDAQ:TGTX): Q3 GAAP EPS of $0.02 misses by $0.01. Revenue of